Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other financing activities (2016 - 2022)

Syndax Pharmaceuticals (SNDX) has 8 years of Other financing activities data on record, last reported at $92000.0 in Q1 2022.

  • For Q1 2022, Other financing activities rose 16.46% year-over-year to $92000.0; the TTM value through Mar 2022 reached $13000.0, down 18.75%, while the annual FY2020 figure was $1000.0, 99.45% down from the prior year.
  • Other financing activities reached $92000.0 in Q1 2022 per SNDX's latest filing, up from -$242000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $99000.0 in Q3 2021 and bottomed at -$242000.0 in Q4 2020.
  • Average Other financing activities over 5 years is $24764.7, with a median of $57000.0 recorded in 2019.
  • Peak YoY movement for Other financing activities: soared 3500.0% in 2018, then tumbled 524.56% in 2020.
  • A 5-year view of Other financing activities shows it stood at $17000.0 in 2018, then surged by 235.29% to $57000.0 in 2019, then crashed by 524.56% to -$242000.0 in 2020, then changed by 0.0% to -$242000.0 in 2021, then skyrocketed by 138.02% to $92000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $92000.0 in Q1 2022, -$242000.0 in Q4 2021, and $99000.0 in Q3 2021.